Ilias Goranitis^1
1The University of Melbourne

Genomic medicine is changing the diagnostic, clinical and therapeutic paradigm for multiple conditions. To enable the significant opportunities of genomic medicine, governments globally are making large investments, with the Global Alliance for Genomics and Health predicting that genomic data for over 330 million patients worldwide will be generated by 2030. These investments in genomic medicine, however, could fail to deliver their full benefit if they are not evaluated appropriately and integrated sustainably into the health system. A significant lack of quantitative evidence for how genomics will benefit the lives and livelihoods of Australians was identified, highlighting a critical need for health and economic data to demonstrate the value genomics can deliver to the health system and to guide national implementation approaches. Over the past 7 years, the development and application of innovative health economic methods to measure the value and value for money of genomics has been a key research priority area for Australian Genomics. This presentation will reflect upon a series of novel: a) preference-elicitation studies with over 3,500 members of the Australian public and study participants undertaken to quantify the value of the diagnostic, clinical and personal outcomes of genomics; b) economic evaluations to assess the relative cost-effectiveness and cost-benefit of genomics in contexts, such as mitochondrial disorders, paediatric critical care, and genetic kidney disease. It will provide insights into how health economics have been used to inform healthcare decision making and contribute to the equitable and sustainable translation of genomics and the design of high value genetic services.